Galera Therapeutics, Inc. (GRTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Galera Therapeutics, Inc. (GRTX) trades at $0.09 with AI Score 50/100 (Grade B). Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to transform radiotherapy in cancer treatment. Market cap: $6.69M, Sector: Healthcare.
Price live · AI analysis from May 8, 2026Analyst Coverage for GRTX: GRTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRTX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GRTX: the 1 perspectives are evenly split.
How is this calculated? →Galera Therapeutics, Inc. (GRTX) Healthcare & Pipeline Overview
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapies to mitigate the side effects of radiotherapy in cancer treatment. Their lead candidate, avasopasem manganese (GC4419), addresses severe oral mucositis, positioning the company within the oncology support care market.
What Is the Investment Thesis for GRTX?
Galera Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful commercialization of avasopasem manganese (GC4419) for radiotherapy-induced severe oral mucositis (SOM). Positive Phase III trial results provide a foundation, but regulatory approval and market adoption remain uncertain. Growth catalysts include potential FDA approval for avasopasem and advancement of GC4711 through clinical trials. Key risks include clinical trial failures, regulatory hurdles, and limited financial resources, given the company's small market capitalization of $6.69M and reliance on future funding. The company's P/E ratio is 0.1.
Based on FMP financials and quantitative analysis
GRTX Key Highlights
- Lead product candidate, avasopasem manganese (GC4419), completed Phase III clinical trial for radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients.
- GC4419 is in Phase IIa clinical trial for radiotherapy-induced esophagitis in lung cancer patients.
- GC4711, a superoxide dismutase mimetic, is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer and locally advanced pancreatic cancer.
- The company has a small market capitalization of $6.69M.
- Galera Therapeutics operates with a lean team of 3 employees.
Who Are GRTX's Competitors?
GRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABCL AbCellera Biologics Inc. | $7.87 | -2.96% | $2.40B | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRTX's Key Strengths?
- Promising lead product candidate (avasopasem) with positive Phase III results.
- Targeting a significant unmet need in cancer supportive care.
- Proprietary superoxide dismutase mimetic technology.
- Pipeline of product candidates in various stages of clinical development.
What Are GRTX's Weaknesses?
- Limited financial resources and reliance on future funding.
- Small team and limited infrastructure.
- High risk associated with clinical-stage biopharmaceutical development.
- Dependence on the success of a limited number of product candidates.
What Could Drive GRTX Stock Higher?
- Potential FDA approval decision for avasopasem manganese (GC4419) for radiotherapy-induced severe oral mucositis (SOM).
- Advancement of GC4711 through Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT).
- Publication of clinical trial results in peer-reviewed journals.
- Potential strategic partnerships and collaborations with larger pharmaceutical companies.
What Are the Key Risks for GRTX?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for avasopasem or GC4711.
- Regulatory hurdles and rejection of product candidates by the FDA.
- Limited financial resources and reliance on future funding.
- Competition from other companies developing similar therapies.
- Changes in the regulatory landscape or reimbursement policies.
What Are the Growth Opportunities for GRTX?
- FDA Approval and Commercialization of Avasopasem for SOM: The successful FDA approval and subsequent commercialization of avasopasem for radiotherapy-induced severe oral mucositis (SOM) represents a significant growth opportunity. The market for SOM treatments is substantial, driven by the high incidence of head and neck cancer patients undergoing radiotherapy. Avasopasem's potential to reduce the severity and duration of SOM could lead to significant market penetration, provided the company can establish effective distribution and marketing strategies.
- Expansion of Avasopasem into Radiotherapy-Induced Esophagitis: The ongoing Phase IIa clinical trial of avasopasem for radiotherapy-induced esophagitis in lung cancer patients offers another avenue for growth. If the trial demonstrates positive results, Galera could expand the label for avasopasem to include this indication, addressing a significant unmet need in lung cancer treatment. The market for esophagitis treatments is sizable, and a successful expansion could significantly increase avasopasem's market potential.
- Advancement of GC4711 in Combination with SBRT: The development of GC4711 in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer and locally advanced pancreatic cancer represents a longer-term growth opportunity. Positive results from the Phase I/II clinical trial could pave the way for further development and eventual commercialization. The market for SBRT combination therapies is growing, driven by the increasing use of SBRT in cancer treatment.
- Strategic Partnerships and Collaborations: Galera could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations could provide access to additional funding, expertise, and distribution channels, enhancing the company's ability to bring its therapies to market. These partnerships could also validate Galera's technology and attract further investment.
- Expansion into New Therapeutic Areas: While currently focused on SOM and esophagitis, Galera could explore the potential of its superoxide dismutase mimetics in other therapeutic areas where oxidative stress plays a role. This could include other radiation-induced toxicities or even non-oncology indications. Expanding the pipeline into new therapeutic areas would diversify the company's risk and create additional growth opportunities.
What Opportunities Does GRTX Have?
- FDA approval and commercialization of avasopasem.
- Expansion of avasopasem into new indications (e.g., esophagitis).
- Advancement of GC4711 through clinical trials.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
What Threats Does GRTX Face?
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of product candidates.
- Competition from other companies developing similar therapies.
- Changes in the regulatory landscape or reimbursement policies.
What Are GRTX's Competitive Advantages?
- Proprietary superoxide dismutase mimetic technology.
- Clinical trial data demonstrating efficacy in reducing radiotherapy side effects.
- Intellectual property protection for their product candidates.
- First-mover advantage in targeting specific radiotherapy side effects.
What Does GRTX Do?
Galera Therapeutics, Inc., founded in 2012 and headquartered in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to transforming radiotherapy in cancer treatment. The company focuses on developing and commercializing novel therapeutics that reduce the debilitating side effects associated with radiation therapy, thereby improving patient outcomes and quality of life. Galera's lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic. Avasopasem has completed a Phase III clinical trial for the treatment of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer (HNC). Additionally, avasopasem is in Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients and for HNC patients undergoing standard-of-care radiotherapy. Galera is also developing GC4711, another superoxide dismutase mimetic, currently in a Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer and locally advanced pancreatic cancer. The company's pipeline targets significant unmet needs in cancer supportive care, aiming to provide effective solutions for patients undergoing radiotherapy.
What Products and Services Does GRTX Offer?
- Develop and commercialize therapeutics for cancer treatment.
- Focus on mitigating the side effects of radiotherapy.
- Develop small molecule superoxide dismutase mimetics.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Seek regulatory approval from the FDA for their therapies.
- Commercialize approved therapies through marketing and distribution efforts.
How Does GRTX Make Money?
- Develop novel therapeutics targeting radiotherapy side effects.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval from the FDA.
- Commercialize approved products through sales and marketing.
What Industry Does GRTX Operate In?
Galera Therapeutics operates within the biotechnology industry, specifically targeting the oncology supportive care market. This market addresses the unmet needs of cancer patients undergoing radiotherapy, focusing on mitigating side effects like oral mucositis and esophagitis. The competitive landscape includes companies developing similar supportive care therapies. The oncology supportive care market is driven by the increasing incidence of cancer and the growing use of radiotherapy as a treatment modality. The company's success depends on its ability to navigate regulatory pathways and secure market share in a competitive environment.
Who Are GRTX's Key Customers?
- Cancer patients undergoing radiotherapy.
- Oncologists and radiation oncologists.
- Hospitals and cancer treatment centers.
- Healthcare providers involved in cancer care.
F-Score 2/9Financial Health
Galera Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
P/E 0.1Key Financial Metrics
GRTX trades at a trailing price-to-earnings ratio of 0.07, below the Healthcare sector average of ~23x. Its free cash flow yield is -44.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.31 indicates the company holds enough short-term assets to cover its near-term obligations.
Galera Therapeutics, Inc. (GRTX) Valuation Context
Valued at $6.69M, GRTX is classified as a micro-cap stock. Relative to its peer group, GRTX's quantitative score of 50/100 is below the peer average of 76/100.
GRTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Galera's pipeline, aligning interests with shareholders.
- Positive community sentiment indicates growing belief in avasopasem manganese's potential impact on cancer treatment side effects.
- The company's focus on addressing unmet needs in radiotherapy-induced toxicities positions them favorably in a niche market.
- Market perception seems to be shifting towards recognizing the value of targeted therapies in mitigating cancer treatment complications, benefiting Galera.
Bear Case
- Limited commercial success to date raises concerns about Galera's ability to effectively market avasopasem manganese.
- Bearish community views reflect skepticism regarding the drug's efficacy and regulatory approval prospects.
- The competitive landscape in cancer supportive care is intensifying, potentially eroding Galera's market share.
- Recent market developments highlight increased scrutiny of biotech companies with single-product pipelines, creating uncertainty for Galera.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GRTX Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Jul 15, 2022
GRTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRTX.
Price Targets
Wall Street price target analysis for GRTX.
GRTX MoonshotScore
What does this score mean?
The MoonshotScore rates GRTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: J. Mel Sorensen
CEO
J. Mel Sorensen serves as the CEO of Galera Therapeutics, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and drug development. Sorensen has held leadership positions at various biotechnology companies, where he oversaw clinical development programs, regulatory submissions, and commercialization strategies. His expertise spans from early-stage research to late-stage development and market launch. He has a proven track record of building and leading successful teams in the biopharmaceutical sector.
Track Record: Under J. Mel Sorensen's leadership, Galera Therapeutics has advanced avasopasem manganese (GC4419) through Phase III clinical trials for radiotherapy-induced severe oral mucositis. He has focused the company's strategy on addressing unmet needs in cancer supportive care. Sorensen has also overseen the development of GC4711 and guided the company through various financing rounds to support its clinical programs.
GRTX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Galera Therapeutics may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and greater volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Potential for low trading volume and wide bid-ask spreads.
- Increased risk of fraud or manipulation.
- Greater price volatility compared to listed stocks.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's capital structure and financing needs.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Completion of Phase III clinical trials for avasopasem.
- Focus on addressing a significant unmet need in cancer supportive care.
- Presence of a CEO with experience in the biopharmaceutical industry.
- Development of proprietary superoxide dismutase mimetic technology.
- Intellectual property protection for their product candidates.
Galera Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Galera Therapeutics, Inc. do?
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies that reduce the side effects of radiotherapy in cancer treatment. Their lead product candidate, avasopasem manganese (GC4419), is designed to reduce the severity and duration of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer. The company is also developing GC4711, another superoxide dismutase mimetic, for use in combination with stereotactic body radiation therapy (SBRT) in non-small cell lung cancer and locally advanced pancreatic cancer. Galera's goal is to improve the quality of life for cancer patients undergoing radiotherapy.
What do analysts say about GRTX stock?
Analyst coverage of Galera Therapeutics (GRTX) is limited, reflecting the company's small market capitalization and OTC listing. Available analysis focuses on the potential of avasopasem manganese (GC4419) to address the unmet need for effective treatments for radiotherapy-induced severe oral mucositis (SOM). Key valuation metrics include potential peak sales of avasopasem and the probability of regulatory approval. Growth considerations center on the successful commercialization of avasopasem and the advancement of GC4711 through clinical trials. Investors should conduct their own due diligence and consider the risks associated with investing in a clinical-stage biopharmaceutical company on the OTC market.
What are the main risks for GRTX?
The main risks for Galera Therapeutics (GRTX) include clinical trial failures, regulatory hurdles, and limited financial resources. The success of the company hinges on the successful development and commercialization of avasopasem manganese (GC4419) and GC4711. Clinical trial failures or delays could significantly impact the company's value. Regulatory approval is not guaranteed, and the FDA may require additional data or reject the product candidates. Galera's limited financial resources and reliance on future funding also pose a risk, as the company may need to raise additional capital through dilutive financing. Competition from other companies developing similar therapies is another risk factor.
What are the key factors to evaluate for GRTX?
Galera Therapeutics, Inc. (GRTX) holds an AI score of 50/100 (moderate). P/E: 0.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does GRTX data refresh on this page?
GRTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRTX's recent stock price performance?
Galera Therapeutics, Inc. (GRTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product candidate (avasopasem) with positive Phase III results. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRTX overvalued or undervalued right now?
Galera Therapeutics, Inc. (GRTX) trades at 0.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GRTX?
Before investing in Galera Therapeutics, Inc. (GRTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited or less reliable than data for listed stocks.
- Clinical trial outcomes are inherently uncertain.